Evidence map›Paper›PMID 35408891›Full record

ArticleInternational journal of molecular sciences2022

Expression of Irisin/FNDC5 in Breast Cancer.

Kamil Cebulski, Katarzyna Nowińska, Karolina Jablońska, Hanna Romanowicz, Beata Smolarz, Piotr Dzięgiel, Marzenna Podhorska-Okołów

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Molecular Research and Treatment of Breast Cancer 2.0.International journal of molecular sciences · 2024
    Article
  11. Review
  12. Review
  13. The Role of Irisin/FNDC5 Expression and Its Serum Level in Breast Cancer.International journal of molecular sciences · 2023
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kamil CebulskiDivision of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland.ORCID 0000-0002-3643-8106
Katarzyna NowińskaDivision of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Karolina JablońskaDivision of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland.ORCID 0000-0002-7989-3264
Hanna RomanowiczDepartment of Pathology, Polish Mother Memorial Hospital-Research Institute, 93-338 Lodz, Poland.
Beata SmolarzDepartment of Pathology, Polish Mother Memorial Hospital-Research Institute, 93-338 Lodz, Poland.ORCID 0000-0003-3168-062X
Piotr DzięgielDivision of Histology and Embryology, Department of Human Morphology and Embryology, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Marzenna Podhorska-OkołówDivision of Ultrastructural Research, Wroclaw Medical University, 50-368 Wroclaw, Poland.
Wroclaw Medical University · PLPolish Mother’s Memorial Hospital Research Institute · PL

Funding

Ministry of Science and Higher education 016/RID/2018/2019Wrocław Medical University ST.SUB.A352.19.030
6 · The paper itself

Abstract

Irisin is a myokine formed from fibronectin type III domain-containing protein 5 (FNDC5), which can be found in various cancer tissues. FNDC5 and irisin levels have been poorly studied in the tumor tissues of breast cancer (BC). The aim of this study was to determine the levels of irisin expression in BC tissues and compare them to clinicopathological factors and Ki-67 and PGC-1α expression levels. Tissue microarrays (TMAs) with 541 BC tissues and 61 samples of non-malignant breast disease (NMBD; control) were used to perform immunohistochemical reactions.

Indexed as

Breast NeoplasmsFemaleFibronectinsHumansFibronectinsFNDC5 protein, humanbreast cancercancerFNDC5irisinKi-67metastasesPGC-1α

Identifiers

PMID35408891
PMCPMC8998925
OpenAlexW4220891910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.